Search Results for:
-
Venture Capital And Other Investments In Private Biotechnology Companies: January 2013
Redwood City, Calif. $25 Versartis raised $25M in a Series C round with Aisling Capital, Index Ventures, New Leaf Partners and Advent Venture Partners 1/16/13 Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld InternationalBioWorld Insight | Monday, February 11, 2013 -
'Safari,' So Good: Africa Tracks to Become Pharma Hot Spot
The fact is, Africa has stabilized," Rosen told BioWorld InternationalBio Perspectives | Wednesday, February 6, 2013 -
New Era Beckons for Zealand as Lyxumia Gains Approval
Zealand CEO David Solomon told BioWorld International...Additional information will be provided at the time of individual country launches," Phil McNamara, spokesman for Sanofi's global diabetes division, told BioWorld InternationalBio Perspectives | Wednesday, February 6, 2013 -
BIA Widening Public Start-up Biotech Investment via CIFs
In addition, since the BIA first put forward the plan in September 2012, it has had a number of positive discussions with other organizations which are interested in the scheme. (See BioWorld International, Sept. 5, 2012.) Figures for the French innovation funds show that for every €1 in tax relief given by the government, €5 of additional private investment is raisedBy Nuala Moran | BioWorld International | Wednesday, February 6, 2013 -
Let 'EdRIP': VC Fund Seeks $677M for Life Science Firms
Litzka told BioWorld International that €250 million remains as the ambition, but "economic realities" may mean the final close is lowerBy Nuala Moran | BioWorld International | Wednesday, February 6, 2013 -
New Era Beckons for Zealand as Lyxumia Gains Approval
Zealand CEO David Solomon told BioWorld International...Additional information will be provided at the time of individual country launches," Phil McNamara, spokesman for Sanofi's global diabetes division, told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 6, 2013 -
AC Immune Drops ACI-91 on Phase II Alzheimer's Failure
They had activity showing they could protect neurons against the toxic effects of Abeta," AC Immune CEO Andrea Pfeifer told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 6, 2013 -
Control of Cancer, Not Killing, Is Key to Treatment: Study
Martin Röcken, director of the department of dermatology of the University Medical Center Tübingen, told BioWorld International: "We are currently applying for a grant to fund a study of this therapy in patients with metastatic malignant melanoma, in which we would take the patient's T cells, prime them with a cancer peptide and then put them back in to the patient's bodyBy Sharon Kingman | BioWorld International | Wednesday, February 6, 2013 -
Gamida Cell's StemEx Improves Overall Survival in Phase II/III
Partnering has significant advantages, but you have to find the right partner," Margolin told BioWorld International, noting that the company will entertain those discussions after meeting with the FDABy Marie Powers | BioWorld International | Wednesday, February 6, 2013 -
'Safari,' So Good: Africa Tracks to Become Pharma Hot Spot
The fact is, Africa has stabilized," Rosen told BioWorld InternationalBy Randy Osborne | BioWorld International | Wednesday, February 6, 2013 -
Active Biotech's Immunotherapy Anyara Is Down but Not Out
We're encouraged that we got a robust signal," CEO Thomas Leanderson told BioWorld InternationalBio Perspectives | Wednesday, January 30, 2013 -
Active Biotech's Immunotherapy Anyara Is Down but Not Out
We're encouraged that we got a robust signal," CEO Thomas Leanderson told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, January 30, 2013 -
WLSF Fund to Invest $160M, Bring Life Sciences to Wales
It took a long time to pull them all together, but we are now announcing the 10-man, high-profile board and the first investment is imminent," Martin Walton, one of the Arthurian directors, told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, January 30, 2013 -
Genetic Study Reveals 'Critical' Gene in Melanoma Development
Rajiv Kumar, professor of molecular genetic epidemiology at the German Cancer Research Center in Heidelberg, Germany, told BioWorld International: "We have discovered new mutations in a critical gene for malignant melanoma, which might explain the formation of this tumorBy Sharon Kingman | BioWorld International | Wednesday, January 30, 2013 -
Avillion Gets Initial Funding, Helps Pharma Pick Up Pace
Using this model we can make pipeline development go faster," Cameron told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, January 30, 2013 -
Bone Therapeutics Gets $10M for Cell Therapy Development
A Phase III trial of the autologous cell therapy in osteonecrosis, a degenerative bone disease caused by a loss of blood supply to the bone, is ongoing. (See BioWorld International, Nov. 14, 2012.) Preob comprises preosteoblast cells, which are derived from mesenchymal stem cells obtained from each patient's bone marrow...Those cells have not been genetically engineered, but they have been cultured in conditions that prevent expression of major histocompatibility markers, CEO Enrico BastianelliBy Cormac Sheridan | BioWorld International | Wednesday, January 30, 2013 -
Gene Signal Raises New Cash for Its Antisense Drug Trials
Now we are in a position where we have raised enough money to cover the next three years of development, in orphan and non-orphan indications," Gene Signal CEO and co-founder Eric Viaud told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, January 30, 2013 -
Bone Therapeutics Gets $10M For Cell Therapy Development
A Phase III trial of the autologous cell therapy in osteonecrosis, a degenerative bone disease caused by a loss of blood supply to the bone, is ongoing. (See BioWorld International, Nov. 14, 2012.) Preob comprises preosteoblast cells, which are derived from mesenchymal stem cells obtained from each patient's bone marrowBy Cormac Sheridan | BioWorld Today | Tuesday, January 29, 2013 -
EMA's CHMP Declines to OK Santhera's Raxone for Blindness
We're not disclosing the size of the majority against, but we do know, and I can confirm it's very narrow," Thomas Meier, CEO of Raxone's developer Santhera Pharmaceuticals AG, told BioWorld InternationalBio Perspectives | Wednesday, January 23, 2013 -
Start-up Dezima Taking on Big Pharma in CETP Inhibition
We expect the data to be available in the second quarter of 2014," Sander van Deventer, interim CEO of Dezima and general partner of Forbion Capital Partners, told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, January 23, 2013
Category
Current Filters
- xBioWorld International
Related Keywords
Categories
- x BioWorld International (5413)
- x BioWorld Insight (594)
- x BioWorld Today (335)
- x Bio Perspectives (195)
- x State of the Industry Report (47)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.